MHRA
- Local brand name: Axitinib Accord
- Status: approved
🇬🇧 Inlyta in United Kingdom
NICE has issued 3 UK HTA decisions
Marketing authorisation
Health technology assessment
3 decisions from NICE for Inlyta in United Kingdom.
NICE TA333 — ✓ Recommended
- Indication assessed: treating advanced renal cell carcinoma after failure of prior systemic treatment
NICE recommended Inlyta for treating advanced renal cell carcinoma after failure of prior systemic treatment. This decision was made based on the drug's clinical effectiveness and a commercial arrangement with the manufacturer. No restrictions were placed on the use of Inlyta.
NICE TA1120 — — Decision pending classification
- Indication assessed: untreated advanced renal cell carcinoma
NICE recommended Inlyta for the treatment of untreated advanced renal cell carcinoma. The decision was made based on a commercial arrangement, indicating that the manufacturer agreed to a specific price or terms for the drug. No restrictions or conditions were placed on the use of Inlyta.
NICE TA650 — ✗ Not recommended
- Indication assessed: untreated advanced renal cell carcinoma
NICE did not recommend Inlyta for the treatment of untreated advanced renal cell carcinoma. This decision was made without a reported cost-effectiveness analysis. No restrictions or conditions were placed on the use of Inlyta.
Inlyta in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Inlyta approved in United Kingdom?
Yes. MHRA has authorised it.
Who is the marketing authorisation holder for Inlyta in United Kingdom?
Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.
Has Inlyta been assessed by UK health technology agencies?
Yes — 3 UK HTA decisions on record from NICE.